Janice M. Mehnert

Also affiliated with Ralph Lauren Center for Cancer Care and Prevention, New York University

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “A multicenter characterization of hepatitis associated with immune checkpoint inhibitors”.

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

OncoImmunology(2021)10.1080/2162402x.2021.1875639

N/A

2.2DataRank · unranked

63 citations

Ben McGuigan, Sunandana Chandra, Sarah E. Fenton, Akansha Chowdhary, Lucy Boyce Kennedy +14 more

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

Frontiers in Oncology(2020)10.3389/fonc.2019.01483

N/A

0.865DataRank · unranked

12 citations

Howard L. Kaufman, Brendan D. Curti, Janice M. Mehnert, Kim Margolin, David F. McDermott +10 more

Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9591

N/A

0.292DataRank · unranked

6 citations

Aleigha Lawless, Rachel Woodford, Faisal Fa’ak, Asha Tipirneni, James R. Patrinely +11 more

Association of pre-existing autoimmune diseases in melanoma patients receiving immune checkpoint inhibition with improved survival and increased toxicity.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e21586

N/A

0DataRank · unranked

0 citations

Arda Celen, Paul Johannet, Amelia Sawyers, Min Jae Kim, Janice M. Mehnert +5 more

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0404

N/A

0DataRank · unranked

41 citations

Wenke Liu, David Fenyö, Megan Wind‐Rotolo, Michelle Krogsgaard, Janice M. Mehnert +4 more

Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment

Journal of Investigative Dermatology(2022)10.1016/j.jid.2022.07.022

N/A

0DataRank · unranked

13 citations

Irineu Illa-Bochaca, Milad Ibrahim, Douglas M. Donnelly, Kelsey Zhu, Eleazar Vega‐Saenz de Miera +9 more

Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9549

N/A

0DataRank · unranked

0 citations

Paola Angulo, Faisal Fa’ak, Noha Abdel‐Wahab, Adi Diab, Janice M. Mehnert +6 more

Evolution of Rapid Clonal Dynamics and Non–Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer

JCO Precision Oncology(2024)10.1200/po.23.00260

N/A

0DataRank · unranked

5 citations

Jillian N. Carrick, Stephanie L. Murphy, Om A. Kothari, Husam Al-Hraishami, Atul Kulkarni +15 more

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10039

N/A

0DataRank · unranked

1 citations

Megan Othus, Adil Daud, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry +15 more

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.0051

N/A

0DataRank · unranked

254 citations

Rebecca Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova +15 more